Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.85
-0.52 (-1.08%)
At close: Jun 27, 2025, 4:00 PM
48.05
+0.20 (0.42%)
After-hours: Jun 27, 2025, 7:46 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B EUR
Revenue Growth
-2.42%
P/S Ratio
2.41
Revenue / Employee
544,970 EUR
Employees
82,878
Market Cap
117.74B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SNY News
- 2 days ago - Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts - PRNewsWire
- 3 days ago - Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation - GlobeNewsWire
- 8 days ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 8 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 8 days ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 10 days ago - RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports - Reuters
- 10 days ago - RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury - CNBC
- 11 days ago - Press release: Sanofi successfully prices €1.5 billion bond issue - GlobeNewsWire